Skip to main content

Table 3 Dispensed drugs to patients receiving OAT and OAT/DAAs in Norway and Sweden in 2017

From: Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

Year 2017 2017
Country Norway Sweden
OAT study population, n 5543 2739
  Only OAT DAA + OAT Only OAT DAA + OAT
  5177 366 2616 123
Drugs No. (%) No. (%) No. (%) No. (%)
Drugs used in Diabetes 197 (4) 14 (4) 161 (6) 18 (15)
Antithrombotic agents 529 (10) 35 (10) 217 (8) 8 (7)
Cardiovascular system drugs a 842 (16) 67 (18) 622 (24) 37 (30)
Lipid modifying agents 271 (5) 10 (3) 121 (5) 4 (3)
Sex hormones and modulators of genital system 654 (13) 51 (14) 430 (16) 14 (11)
Antibacterials for systemic use 1901 (36) 112 (31) 915 (35) 33 (27)
Anti-inflammatory and ant-rheumatic products 1155 (22) 69 (19) 570 (22) 25 (20)
Drugs for obstructive airway diseases 1048 (20) 68 (19) 410 (16) 14 (11)
Benzodiazepinesb 2368 (46) 181 (50) 402 (15) 19 (15)
Hypnotics and sedativesc 797 (15) 54 (15) 691 (26) 30 (24)
Antiepilepticsd 823 (16) 57 (16) 629 (24) 25 (20)
Antidepressantse 960 (19) 73 (20) 1008 (39) 38 (31)
Antipsychoticsf 1401 (27) 85 (23) 602 (23) 28 (23)
  1. Source: The Swedish Prescribed Drug Register (SPDR), The Norwegian Prescription Database (NorPD). All drugs on ATC Level 2, except under Nervous system. See Supplement Table S2
  2. OAT Opioid agonist therapy, DAA Direct-acting antiviral agents
  3. aC01, C02, C03, C07, C08, C09
  4. bN05BA01, N05BA04, N05BA06, N05BA12, N05CD02, N05CD03, N05CD08, N03AE01
  5. cN05CF01 and N05CF02
  6. dN03AA, N03AB, N03AF, N03AG, N03AX
  7. eN06AA, N06AB, N06AF, N06AG, N06AX
  8. fN05AA, N05AB, N05AC, N05AD, N05AE, N05AF, N05AG, N05AH, N05AL, N05AN, N05AX